Ovarian Cancer Supportive Care Protocol

Oncology/Women's HealthLimited Evidence
5
supplements
2
Primary
3
Supporting
0
Grade A
33
Studies

Primary Stack

Core supplements with strongest evidence
2000-4000 IU daily (optimize levels)

Supports immune function; low levels associated with poorer outcomes

8 studies500 participants
2-3g EPA+DHA daily

Anti-inflammatory; supports immune function; may help with cachexia

6 studies300 participants

Supporting Stack

Additional supplements for enhanced results
1000-2000mg daily (with piperine for absorption)

Anti-inflammatory and antioxidant; being studied as adjunct therapy

5 studies200 participants
10-20 billion CFU daily

May support gut health during chemotherapy; reduce GI side effects

4 studies200 participants
1-2g daily during chemotherapy

Helps with chemotherapy-induced nausea

10 studies500 participants

How This Protocol Works

Simple Explanation

Ovarian cancer is a serious cancer that begins in the ovaries. It often goes undetected until it has spread within the pelvis and abdomen, making it challenging to treat at advanced stages.

TYPES:

•Epithelial ovarian cancer: Most common (~90%)
•Germ cell tumors: Usually in younger women
•Stromal tumors: Rare

SYMPTOMS (often vague until advanced):

•Bloating
•Pelvic or abdominal pain
•Feeling full quickly when eating
•Urinary frequency
•Fatigue
•Unexplained weight loss

CRITICAL: Ovarian cancer requires comprehensive oncological care. This protocol is SUPPORTIVE ONLY and must be coordinated with your oncology team.

MEDICAL TREATMENTS:

•Surgery: Debulking surgery to remove as much cancer as possible
•Chemotherapy: Platinum-based (carboplatin) + taxane typically
•PARP inhibitors: Olaparib, niraparib for BRCA-mutated tumors
•Bevacizumab: Anti-angiogenic therapy
•Maintenance therapy: To prevent recurrence

GENETIC TESTING:

•BRCA1/BRCA2 testing important
•Affects treatment options and family screening

IMPORTANT CONSIDERATIONS:

•Discuss ALL supplements with your oncologist
•Some supplements may interact with chemotherapy
•Don't delay or replace standard treatment

* Vitamin D and omega-3 support overall health during treatment.

* Ginger can help with chemotherapy-induced nausea.

* Always clear supplements with oncology team.

Expected timeline: Treatment and prognosis depend on stage and type. Supplements provide supportive care during treatment journey.

Clinical Perspective

Ovarian Cancer: Epithelial most common (high-grade serous predominant). Risk factors: BRCA1/2 mutations, Lynch syndrome, family history, nulliparity. Staging is surgical. Treatment: primary debulking surgery + platinum/taxane chemotherapy. PARP inhibitors for maintenance (BRCA-mutated, HRD-positive).

CRITICAL: Supplements must be coordinated with oncology team - potential interactions with chemotherapy. Evidence for supplements in ovarian cancer is limited. Ginger has best evidence for chemo-induced nausea. Vitamin D optimization reasonable. High-dose antioxidants controversial during chemotherapy. Ketogenic diet being studied but not standard. Supportive care focus: nutrition, symptom management, quality of life.

* Vitamin D (C-grade): Immune support. Systematic review: (PMID: 28750270). 2000-4000 IU daily.

* Omega-3 (C-grade): Anti-inflammatory. Review: (PMID: 27840029). 2-3g EPA+DHA daily.

* Curcumin (C-grade): Research interest. Review: (PMID: 27213821). 1000-2000mg daily.

* Probiotics (C-grade): GI support. Systematic review: (PMID: 24045160). 10-20B CFU daily.

* Ginger (B-grade): Antiemetic. Systematic review: (PMID: 21818642). 1-2g daily.

Assessment targets: Response to treatment (CA-125, imaging), symptom control, quality of life, nutritional status.

Protocol notes: Supplements and chemo: always discuss with oncologist; some antioxidants controversial. Ginger: well-studied for CINV; can use with antiemetics. Vitamin D: optimize levels; deficiency common. BRCA testing: affects treatment (PARP inhibitors) and family screening. Nutrition: maintain adequate protein; address cachexia if present. CA-125: monitor during treatment; not for screening. Recurrence: common; maintenance therapy reduces risk. Integrative oncology: many cancer centers offer; coordinate care. Clinical trials: consider enrollment. Palliative care: early integration improves quality of life.